检测循环细胞游离DNA用于淋巴瘤诊断和评估的研究进展

doi:10.16352/j.issn.1001-6325.2022.04.017

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (4): 661-666.doi: 10.16352/j.issn.1001-6325.2022.04.017

检测循环细胞游离DNA用于淋巴瘤诊断和评估的研究进展

白小腾¹, 孙晓红¹, 赵翔宇¹, 李子坚^2*

1.兰州大学第一临床医学院, 甘肃兰州 730030;
2.兰州大学第一医院血液内科, 甘肃兰州 730000

收稿日期:2021-07-13 修回日期:2021-12-08 出版日期:2022-04-05 发布日期:2022-04-01
通讯作者: * ldyy_lizj@lzu.edu.cn
基金资助:
国家自然科学基金(81300427)

Advances in diagnosis and evaluation of lymphoma through the detection of circulating cell free DNA

BAI Xiao-teng¹, SUN Xiao-hong¹, ZHAO Xiang-yu¹, LI Zi-jian^2*

1. the First School of Clinical Medicine, Lanzhou University, Lanzhou 730030;
2. Department of Hematology,the First Hospital of Lanzhou University, Lanzhou 730000, China

Received:2021-07-13 Revised:2021-12-08 Online:2022-04-05 Published:2022-04-01
Contact: * ldyy_lizj@lzu.edu.cn

摘要/Abstract

摘要： 随着基因检测技术的发展,通过外周血对血液中循环细胞游离DNA(cf DNA)的检测日益便捷和低廉,为淋巴瘤患者疾病诊断、预后评估以及治疗后评估和疾病监测提供了新的选择。特别在靶向治疗时代,淋巴瘤分型和诊断越来越趋向于基于基因特征的分型,外周血cf DNA检测的优势日益凸显。

关键词: 循环肿瘤DNA, 淋巴瘤, 诊断, 评估

Abstract: Circulating cell-free DNA(cf DNA) detection in peripheral blood is becoming increasingly convenient and inexpensive with the development of genetic testing technology. It provides a new option for diagnosis, prognosis prediction, post-treatment evaluation and disease surveillance of lymphoma patients. Especially in targeted therapy, lymphoma typing and diagnosis tend to be based on genetic characteristics, and the advantages of cf DNA detection from peripheral blood sample increasingly prominent.

Key words: circulating cell-free DNA, lymphoma, diagnosis, evaluation

中图分类号:

R446.9

白小腾, 孙晓红, 赵翔宇, 李子坚. 检测循环细胞游离DNA用于淋巴瘤诊断和评估的研究进展[J]. 基础医学与临床, 2022, 42(4): 661-666.

BAI Xiao-teng, SUN Xiao-hong, ZHAO Xiang-yu, LI Zi-jian. Advances in diagnosis and evaluation of lymphoma through the detection of circulating cell free DNA[J]. Basic & Clinical Medicine, 2022, 42(4): 661-666.

参考文献

[1] Younes A, Sehn LH, Johnson P, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma[J]. J Clin Oncol, 2019, 37: 1285-1295.
[2] Nowakowski GS, Chiappella A, Witzig TE, et al. ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma[J]. Future Oncol, 2016, 12: 1553-1563.
[3] Snyder MW, Kircher M, Hill AJ, et al. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin[J]. Cell, 2016, 164: 57-68.
[4] Mathai RA, Vidya RVS, Reddy BS, et al. Potential utility of liquid biopsy as a diagnostic and prognostic tool for the assessment of solid tumors: implications in the precision oncology[J]. J Clin Med, 2019, 8:373. doi: 10.3390/jcm8030373.
[5] 钟凌, 贾永前, 孟文彤, 等. 非霍奇金淋巴瘤患者血浆游离DNA IgH和TCRγ基因重排的检测及临床意义[J]. 中华血液学杂志,2008,29: 258-262.
[6] 陈园园, 郭素青, 李英华, 等. 血循环DNA在淋巴瘤中的定量检测及其临床意义[J]. 中国实验血液学杂志, 2016, 24: 1390-1396.
[7] Jianqiu W, Weiyan T, Laiquan H, et al. The analysis of cell-free DNA concentrations and integrity in serum of initial and treated of lymphoma patients[J]. Clin biochem, 2019, 63:59-65.
[8] Tao K, Wang X, Tian X. Relapsed primary central nervous system lymphoma: current advances[J]. Front Oncol, 2021, 11: 649789. doi: 10.3389/fonc.2021.649789.
[9] Rimelen V, Ahle G, Pencreach E, et al. Tumor cell-free DNA detection in CSF for primary CNS lymphoma diagnosis[J]. Acta Neuropathol Commun, 2019, 7: 43. doi: 10.1186/s40478-019-0692-8.
[10] Hickmann AK, Frick M, Hadaschik D, et al. Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas[J]. BMC Cancer, 2019, 19: 192. doi: 10.1186/s12885-019-5394-x.
[11] Liu H, Yang C, Zhao X, et al. Genotyping on ctDNA identifies shifts in mutation spectrum between newly diagnosed and relapse/refractory DLBCL[J]. Onco Targets Ther, 2020, 13: 10797-10806.
[12] Kurtz DM, Green MR, Bratman SV, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing[J]. Blood, 2015, 125: 3679-3687.
[13] Roschewski M, Dunleavy K, Pittaluga S, et al. Circulat-ing tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study[J]. Lancet Oncol, 2015, 16: 541-549.
[14] Scherer F, Kurtz DM, Newman AM, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA[J]. Sci Transl Med, 2016, 9.doi:10.1126/scitranslmed.aai8545.
[15] Rivas-Delgado A, Nadeu F, Enjuanes A, et al. Muta-tional landscape and tumor burden assessed by cell-free DNA in diffuse large B-cell lymphoma in a population-based study[J]. Clin Cancer Res, 2021, 27: 513-521.
[16] Zhou L, Zhao H, Shao Y, et al. Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor t therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment[J]. J Cancer, 2021, 12: 5423-5431.
[17] Chase ML,Armand P. Minimal residual disease in non-hodgkin lymphoma-current applications and future directions[J]. Br J Haematol, 2018, 180: 177-188.
[18] Mauz-Korholz C, Metzger ML, Kelly KM, et al. Pediatric Hodgkin lymphoma[J]. J Clin Oncol, 2015, 33: 2975-2985.
[19] Bessi L, Viailly PJ, Bohers E, et al. Somatic mutations of cell-free circulating DNA detected by targeted next-generation sequencing and digital droplet PCR in classical hodgkin lymphoma[J]. Leuk Lymphoma, 2019, 60: 498-502.
[20] Desch AK, Hartung K, Botzen A, et al. Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma[J]. Leukemia, 2020, 34: 151-166.
[21] Shi Y, Su H, Song Y, et al. Circulating tumor DNA predicts response in chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab[J]. EBioMedicine, 2020, 54: 102731. doi: 10.1016/j.ebiom.2020.102731.
[22] Delfau-Larue MH, van der Gucht A, Dupuis J, et al. Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma[J]. Blood Adv, 2018, 2: 807-816.
[23] Camus V,Jardin F. Cell-free DNA and the monitoring of lymphoma treatment[J]. Pharmacogenomics, 2019, 20: 1271-1282.
[24] Zhong Y, Xu F, Wu J, et al. Application of next generation sequencing in laboratory medicine[J]. Ann Lab Med, 2021, 41: 25-43.
[25] Noguchi T, Sakai K, Iwahashi N, et al. Changes in the gene mutation profiles of circulating tumor DNA detected using CAPP-seq in neoadjuvant chemotherapy-treated advanced ovarian cancer[J]. Oncol Lett, 2020, 19: 2713-2720.
[26] Rossi D, Diop F, Spaccarotella E, et al. Diffuse large B-cell lymphoma genotyping on the liquid biopsy[J]. Blood, 2017, 129: 1947-1957.
[27] Vitale SR, Groenendijk FH, van Marion R, et al. TP53 mutations in serum circulating cell-free tumor DNA as longitudinal biomarker for high-grade serous ovarian cancer[J]. Biomolecules, 2020, 10: 415. doi: 10.3390/biom10030415.

检测循环细胞游离DNA用于淋巴瘤诊断和评估的研究进展

Advances in diagnosis and evaluation of lymphoma through the detection of circulating cell free DNA

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	付志刚, 覃佳, 谭江山. 门脉高压性肺动脉高压:诊治进展与挑战[J]. 基础医学与临床, 2024, 44(8): 1068-1073.
[2]	谢芳菲, 李双玲, 王春梅. ICU危重患者静脉血栓栓塞症预防策略[J]. 基础医学与临床, 2024, 44(7): 906-911.
[3]	胡潮兴, 梁秋冬, 吴大鹏. 血清SAA4和SOCS1对脊柱结核与化脓性脊柱炎的早期鉴别价值[J]. 基础医学与临床, 2024, 44(7): 997-1001.
[4]	张睿, 谭妍, 马东来, 王蓉蓉, 张学. KIT杂合大片段缺失导致斑驳病一家系的临床表型[J]. 基础医学与临床, 2024, 44(7): 954-958.
[5]	王宇, 童安莉, 周玥, 张文倩, 崔云英, 景红丽, 李玉秀. ^99mTc-HYNIC-TOC显像和¹³¹I-MIBG显像在嗜铬细胞瘤和副神经节瘤中的诊断价值[J]. 基础医学与临床, 2024, 44(3): 374-378.
[6]	李瑗春, 严学倩, 范丹, 及月茹, 肖方, 高静. AP2M1抑制弥漫性大B细胞淋巴瘤细胞增殖和侵袭[J]. 基础医学与临床, 2024, 44(3): 308-316.
[7]	赵永忠, 薛懿, 李立群, 侯孟森, 杨晓军. 胆囊癌的早期影像学及循环标志物特征[J]. 基础医学与临床, 2024, 44(2): 265-269.
[8]	依马木买买提江·阿布拉, 帕哈尔丁·白克热, 易超, 佟庆. 血浆hsa_circ_005230在原发性肝细胞癌诊断和预后评估中的临床价值[J]. 基础医学与临床, 2023, 43(9): 1417-1422.
[9]	颜晨红, 金儿. 外泌体PD-L1在非小细胞肺癌诊断和治疗上的研究进展[J]. 基础医学与临床, 2023, 43(9): 1457-1461.
[10]	代娣, 刘玉琴. 原发性胃淋巴瘤的诊断难点及治疗进展[J]. 基础医学与临床, 2023, 43(9): 1462-1466.
[11]	王含必, 陈洁, 张志媛, 赵春霞, 武童, 孙爱军. 合理设立考试内容及节点对培训效果的积极影响[J]. 基础医学与临床, 2023, 43(8): 1326-1329.
[12]	乔逸, 肖河, 罗涵青, 樊晓红, 王鸥, 李融融, 于阳, 纪志刚, 李汉忠. 泌尿系结石代谢评估的“协和模式”初步成果的评价[J]. 基础医学与临床, 2023, 43(5): 804-808.
[13]	戴靖榕, 李婕, 何旭, 李杨, 李燕. 云南省某医院老年医学科住院患者认知功能障碍的患病率及影响因素分析[J]. 基础医学与临床, 2023, 43(3): 468-475.
[14]	宋桉, 李冉, 刘艺文, 周翔, 段炼, 王鸥, 李玉秀. 多元化教学在八年制医学生内分泌科临床教学中的应用[J]. 基础医学与临床, 2023, 43(10): 1620-1624.
[15]	杜明月, 李学广, 左珊如, 陈紫淇, 周军华, 厉浩, 贺权源. 人工智能在癌诊断和治疗中的应用进展[J]. 基础医学与临床, 2022, 42(8): 1297-1301.